Eczema Trial, Recruiting (NCT06756438)

Eczema Trial, Recruiting NCT06756438 Sponsor: NAOS Les Laboratoires Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT06756438 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children aged 3 months to 12 years old, of any sex
Children with a skin tone classified as phototype I to IV (fair to olive skin tones — confirm with trial site)
Children who have atopic (dry, allergy-prone) skin and sensitive skin
Children who have had at least 3 eczema flare-ups in the 6 months before the study starts, including one flare-up observed at the first visit
Children who are experiencing an eczema flare-up at the first visit, for which a dermatologist has prescribed a topical corticosteroid (steroid cream or ointment)
Children whose eczema severity score (called SCORAD) falls between 15 and 40 at the first visit — this measures how serious the eczema is
Children who no longer need medical treatment after using the prescribed steroid cream, and whose eczema symptoms have cleared up by the time the study officially begins
Children who are in generally good health
Children whose parent or legal guardian has freely given informed consent to participate
Children whose parent or legal guardian is willing to follow the study procedures throughout the trial
Children who are Polish citizens

Who may not be able to join:

Children who have a skin condition in the area being studied, other than atopic dermatitis (eczema)
Children who have used topical (applied to skin) or systemic (taken by mouth or injection) treatments in the weeks before the study that could affect the results, including antihistamines (allergy medicines), except for the steroid creams prescribed as part of the study
Children who have had surgery under general anaesthetic within the past month
Children who have had excessive sun or UV exposure in the past month
Children who are already taking part in another clinical trial involving the same areas of skin being studied
Children whose eczema lesions are weeping (oozing liquid) or show any signs of infection, such as pus

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 587320290

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06756438

Sponsor: NAOS Les Laboratoires

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 587320290

More information: https://clinicaltrials.gov/study/NCT06756438

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children aged 3 months to 12 years old, of any sex
Children with a skin tone classified as phototype I to IV (fair to olive skin tones — confirm with trial site)
Children who have atopic (dry, allergy-prone) skin and sensitive skin
Children who have had at least 3 eczema flare-ups in the 6 months before the study starts, including one flare-up observed at the first visit
Children who are experiencing an eczema flare-up at the first visit, for which a dermatologist has prescribed a topical corticosteroid (steroid cream or ointment)
Children whose eczema severity score (called SCORAD) falls between 15 and 40 at the first visit — this measures how serious the eczema is
Children who no longer need medical treatment after using the prescribed steroid cream, and whose eczema symptoms have cleared up by the time the study officially begins
Children who are in generally good health
Children whose parent or legal guardian has freely given informed consent to participate
Children whose parent or legal guardian is willing to follow the study procedures throughout the trial
Children who are Polish citizens

Who may not be able to join:

Children who have a skin condition in the area being studied, other than atopic dermatitis (eczema)
Children who have used topical (applied to skin) or systemic (taken by mouth or injection) treatments in the weeks before the study that could affect the results, including antihistamines (allergy medicines), except for the steroid creams prescribed as part of the study
Children who have had surgery under general anaesthetic within the past month
Children who have had excessive sun or UV exposure in the past month
Children who are already taking part in another clinical trial involving the same areas of skin being studied
Children whose eczema lesions are weeping (oozing liquid) or show any signs of infection, such as pus

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

NAOS Les Laboratoires

Registry

ClinicalTrials.gov

Start date

2 September 2024

Est. completion

1 September 2025

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

SCOring Atopic Dermatisis (SCORAD); SCORING ATOPIC DERMATITIS BY SUBJECT'S PARENT/LEGAL GUARDIAN (PO-SCORAD); CUTANEOUS ACEPTABILITY; Evaluation of "xerosis", "pruritus" and "insomnia" evolution based on SCORAD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov